A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Japanese and Non-Japanese Subjects With Elevated LDL-C
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2013
At a glance
- Drugs Frovocimab (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 07 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.